Journal policy on research funded by the tobacco industry

Fiona Godlee, Ruth Malone, Adam Timmis, Catherine Otto, Andrew Bush, Ian Pavord, Trish Groves

As editors of the BMJ, Heart, Thorax and BMJ Open, we have decided that the journals will no longer consider for publication any study that is partly or wholly funded by the tobacco industry. Our new policy is consistent with those of other journals including PLoS Medicine, PLoS One, PLoS Biology,1 Journal of Health Psychology;2 journals published by the American Thoracic Society;4 and the BMJ’s own Tobacco Control.6

Critics may argue—as many did when journals stopped publishing cigarette advertisements—that publishing such research does not constitute endorsing its findings and that, as long as funding sources are fully disclosed, readers can consider that information and make up their own minds about the quality of the work. Peer review should prevail, goes this line of thinking: it’s not the editor’s job to make these kinds of judgments. However, this view ignores the growing body of evidence that biases and research misconduct are often impossible to detect,7 and that the source of funding can influence the outcomes of studies in invisible ways.6–7

Underlying all the activity of peer review, editing and publishing is the assumption that medical journals exist for the purpose of advancing knowledge that can be used to promote health and reduce disease. But the deputy editor of BMJ, Andrew Bush, observed, ‘The tobacco industry is continuing and is of these companies is continuing and is of these companies is continuing and is of these companies is continuing and is of these companies is continuing and is of these companies is continuing and is still in the business of promoting and selling its deadly products while shoring up its damaged legitimacy.’8

We now know, from extensive research drawing on the tobacco industry’s own internal documents, that for decades the industry sought to create scientific and popular ignorance or ‘doubt.’ At first, this doubt related to the fact that smoking caused lung cancer; later, it related to the harmful effects of secondhand smoke on non-smokers, and the true effects of using so-called light or reduced tar cigarettes on smokers’ health.9–12 Journals unwittingly played a role in producing and sustaining this ignorance.9–9

Some who work within public health and who buy the notion of ‘harm reduction’ argue that the companies that now produce modified cigarette products and non-cigarette tobacco products, including electronic nicotine delivery devices (e-cigarettes), are different from the tobacco industry of old, or that the tobacco industry has changed. For ‘hardened’ cigarette smokers who can’t or won’t quit cigarettes,13 the argument goes, new tobacco products could represent potential public health gains, and company-sponsored research may be the first to identify those gains.

But one fact remains unassailably true: the same few multinational tobacco companies continue to dominate the market globally and, as smaller companies develop promising products, they are quickly acquired by the larger ones. However promising any other products might be, tobacco companies are still in the business of marketing cigarettes. As US federal court judge Gladys Kessler pointed out in her judgment in the case of US Department of Justice versus Philip Morris et al, the egregious behaviour of these companies is continuing and is likely to continue into the future.14 And just this summer, documents leaked from one company showed a concerted campaign to ‘ensure that PP [plain packaging of tobacco products, bearing health warnings but only minimal branding] is not adopted in the UK.’15 The tobacco industry has not changed in any fundamental way, and the cigarette—the single most deadly consumer product ever made—remains widely available and aggressively marketed.

Editors of BMJ journals are committed to integrity in scientific publishing and to ensuring that—as far as possible—their journals publish honest work that advances knowledge about health and disease. Back in 2003, the editor of the BMJ defended publication of a study with tobacco industry funding saying ‘The BMJ is passionately antitobacco, but we are also passionately prodebate and proscience. A ban would be antiscience.’16 But it is time to cease supporting the now discredited notion that tobacco industry-funded research is just like any other research. Refusing to publish research funded by the tobacco industry affirms our fundamental commitment not to allow our journals to be used in the service of an industry that continues to perpetuate the most deadly disease epidemic of our times.

This article is being copublished as an editorial in the BMJ, Heart and Thorax, and as a blog in BMJ Open.

Competing interests None.

Provenance and peer review Not commissioned; not externally peer reviewed.


Accepted 13 September 2013

Published Online First 16 October 2013

doi:10.1136/thoraxjnl-2013-204531

REFERENCES

5 Bero LA, Glanz S, Hong MK. The limits of competing interest disclosures. Tob Control 2005;14:118–26.
8 Rennie D. Integrity in scientific publishing. Health Serv Res 2010;45:885–96.
Journal policy on research funded by the tobacco industry

Fiona Godlee, Ruth Malone, Adam Timmis, Catherine Otto, Andrew Bush, Ian Pavord and Trish Groves

Thorax 2013 68: 1090-1091 originally published online October 15, 2013
doi: 10.1136/thoraxjnl-2013-204531

Updated information and services can be found at:
http://thorax.bmj.com/content/68/12/1090

References

These include:

This article cites 11 articles, 5 of which you can access for free at:
http://thorax.bmj.com/content/68/12/1090#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Health education (1223)
Smoking (1037)
Tobacco use (1039)
Journalology (123)
Health effects of tobacco use (211)
Lung cancer (oncology) (670)
Lung cancer (respiratory medicine) (670)
Lung neoplasms (608)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/